URO ONCO

Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Interview at ESMO 2014 with Dr. Maria De Santis, Vienna, Austria

Improving outcome of patients with muscle invasive bladder cancer
The optimal combination of local and systemic therapy is essential to obtain longer term survival. Level of evidence for adjuvant chemotherapy is limited and trials available on adjuvant chemotherapy are flawed are had problems with accrual. Neoadjuvant chemotherapy is now recommended by the EAU guidelines. Adjuvant chemotherapy is optional according to the EAU-guidelines. No head-to-head comparisons of cystectomy versus radiotherapy are available. Three randomized compared the use of radiotherapy and chemotherapy. 5FU and mitomycine C showed improved survival in combination with radiotherapy in a  recent trial published in the New England Journal of Medicine. Trimodality using TURT, chemotherapy and radiotherapy may be comparable to cystectomy in selected patients but randomized studies in this field are lacking. Chemotherapy alone is not recommended. Radiation, such as hypofractionated schemes is a valuable option for palliation in non-operable muscle invasive bladder cancer.

E-Alert

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Subscribe

URO ONCO is made possible by an unrestricted educational grant from:

The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier.

The journal articles, videos and statements published on the resource centre have been selected independently and without influence from Elsevier, European Urology Editors or the sponsor and do not necessarily reflect their opinions or views.